Recommended Tools
AbSeek™ encompasses antibody sequence analysis, structure and function prediction, lead optimization, de novo generation, and visualization, among others, covering all stages of antibody discovery and engineering from screening to optimization for efficient innovation.
Free Tools Limited Time
Sequence Analysis
Function Prediction
Lead Optimization
Structure Prediction
New
Molecule Generation

Features & Advantages
Integration
Combines multiple algorithms to provide a one-stop service that meets all needs in antibody discovery and engineering.
Expertise
Tailors UI and data visualization methods based on the characteristics of antibody data for better suitability.
Advancement
Continuously updates cutting-edge AI algorithms to ensure the platform's timeliness and advancement.
Data Security
Committed to providing users with a secure and reliable data environment, alleviating concerns about data leakage.
News
Cyagen Talk|AI-Powered Antibody Discovery: From HUGO-Ab Mice to Predictive Models
AbSeek™: Intelligent Antibody Computational Platform
2025-03-19
More >>【Frontier Express】Nature Communications | Molecular Basis of IgLON5 Autoantibody Recognition and Mechanisms of Neurodegeneration
2026-11-07
【Frontier Express】iMeta | Screening for Covalent mIDH1 Inhibitors from Natural Herbs Using a Click Chemistry-Based Protein Chip Platform
2026-11-07
【Frontier Express】Signal Transduction and Targeted Therapy | Efficacy and Safety Evaluation of PEGylated Liposomal Doxorubicin Combined with Dual-Targeted Therapy in Neoadjuvant Treatment of HER2-Positive Breast Cancer
2026-11-06
【Frontier Express】Journal of Hematology & Oncology | First-in-Human Phase Ia Study of BPB-101, a Novel Trifunctional Antibody Targeting the GARP/TGF-β Complex and PD-L1
2026-11-06
【Frontier Express】Advanced Materials | Reshaping De Novo Protein Switches into Bioresponsive Materials for Biomarker, Toxin, and Viral Detection
2026-11-05
【Frontier Express】Lancet (London, England) | Immunogenicity of Fractional Doses of Yellow Fever Vaccine in Ugandan Children: A Randomized Clinical Trial Comparing 1/5 and 1/2 Doses to Full Dose
2026-11-05
【Frontier Express】Nature Communications | Tau Isoform Mapping Reveals Biomarker Signatures Distinguishing Alzheimer's Disease from Amyotrophic Lateral Sclerosis
2026-11-04






